Special Issue

Advances in Drug Targeting for Central Nervous System Disease

Message from the Guest Editors

Currently available drugs offer temporary relief from the symptoms of the neurodegenerative disorder, but they do not arrest or reverse the disease. Adverse effects and resistance to traditional therapies require looking for new options. CNS diseases are multifaceted disorders with diverse and not fully understood pathophysiological mechanisms, e.g., the development of inflammatory processes, oxidative and endoplasmic reticulum stress, disturbance of neuronal-glial communication. The pathological processes are associated with specific signaling pathways, and their elements can become strategic points for development of new drugs and for new applications of already approved. This Special Issue of *Pharmaceutics* titled "Advances in Drug Targeting for Central Nervous System Diseases", will gather discoveries of new drug targets, drug formation and targeted delivery with emphasis on strategies that may alter signaling pathways involved in pathological processes of CNS diseases to stop their progress or even prevent them. Research papers and Reviews on drugs already approved and new molecules are welcome.

Guest Editors

Dr. Ivana Cacciatore

Dr. Anna Wiktorowska-Owczarek

Dr. Sokołowska Paulina

Deadline for manuscript submissions

closed (31 October 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/142673

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, New Jersey 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

